Shi Mengyao, Xue Qian, Xie Jinghui, Yang Qinjun, Tong Jiabing, Zhu Jie, Gao Yating, Ma Xiao, Wu Di, Li Zegeng
Anhui University of Chinese Medicine, Hefei, China.
Chinese Medicine Respiratory Disease Prevention Institute, Hefei, China.
Front Microbiol. 2024 Nov 19;15:1441015. doi: 10.3389/fmicb.2024.1441015. eCollection 2024.
The incidence of chronic obstructive pulmonary disease (COPD) appears to be increasing and evidence suggests that the intestinal flora may play a causative role in its development. Previous studies found that the Shenqi Wenfei Formula (SQWF) can regulate pyroptosis via the NLRP3/GSDMD pathway, thereby reducing the inflammatory response in the lungs of COPD model rats. However, there is no information on whether the drug's effects are associated with intestinal flora. Therefore, this study investigates whether the effects of SQWF are mediated through the regulation of intestinal flora, aiming to elucidate the underlying mechanisms of its therapeutic impact on COPD.
COPD was induced in rats using lipopolysaccharide and cigarette smoke, followed by intragastric administration of SQWF or physiological saline The targets of SQWF, associated signaling pathways, and key bacterial groups were investigated using 16S rRNA sequencing, network pharmacology, and bioinformatics techniques. The prediction results were validated using quantitative reverse transcription PCR, western blotting, and immunofluorescence, among other methods.
SQWF treatment was found to alleviate COPD in model rats. Treatment was also observed to restore the balance of the intestinal flora in the rats, especially by reducing the abundance of . Bioinformatics predictions identified metabolites, RelA, HDAC1, and enriched neutrophil extracellular trap formation pathways as core targets of SQWF in COPD. qRT-PCR and Western blotting results showed that SQWF treatment reduced ReLA and HDAC1 mRNA and protein expression, along with decreased myeloperoxidase and neutrophil elastase levels in the nucleus.
Treatment with SQWF was found to restore the imbalance of intestinal in COPD and also regulate the expression of the ReLA and HDAC1 genes, thereby reducing pulmonary neutrophil extracellular traps and alleviating lung inflammation.
慢性阻塞性肺疾病(COPD)的发病率似乎在上升,有证据表明肠道菌群可能在其发病过程中起致病作用。先前的研究发现,参芪温肺方(SQWF)可通过NLRP3/GSDMD途径调节细胞焦亡,从而减轻COPD模型大鼠肺部的炎症反应。然而,关于该药物的作用是否与肠道菌群有关尚无相关信息。因此,本研究探讨参芪温肺方的作用是否通过调节肠道菌群介导,旨在阐明其对COPD治疗作用的潜在机制。
采用脂多糖和香烟烟雾诱导大鼠患COPD,然后分别给大鼠灌胃参芪温肺方或生理盐水。使用16S rRNA测序、网络药理学和生物信息学技术研究参芪温肺方的作用靶点、相关信号通路和关键菌群。通过定量逆转录PCR、蛋白质印迹和免疫荧光等方法验证预测结果。
发现参芪温肺方治疗可减轻模型大鼠的COPD症状。还观察到该治疗可恢复大鼠肠道菌群的平衡,特别是通过降低……的丰度。生物信息学预测确定……代谢产物、RelA、HDAC1和富集的中性粒细胞胞外诱捕网形成途径是参芪温肺方在COPD中的核心靶点。qRT-PCR和蛋白质印迹结果表明,参芪温肺方治疗可降低ReLA和HDAC1的mRNA和蛋白表达,同时降低细胞核中的髓过氧化物酶和中性粒细胞弹性蛋白酶水平。
发现参芪温肺方治疗可恢复COPD患者肠道菌群的失衡,并调节ReLA和HDAC1基因的表达,从而减少肺部中性粒细胞胞外诱捕网并减轻肺部炎症。